



NDA 50-542/S-022  
NDA 50-754/S-009  
NDA 50-760/S-008  
NDA 50-761/S-008

GlaxoSmithKline  
Attention: Deneen Stewart, Ph.D.  
Assistant Director, U.S. Regulatory Affairs  
One Franklin Plaza  
P.O. Box 7929  
Philadelphia, PA 19101-7929

Dear Dr. Stewart:

Please refer to your supplemental new drug applications dated December 12, 2003, received December 15, 2003, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for:

Amoxil<sup>®</sup> (amoxicillin) 125 mg and 250 mg Chewable Tablets (NDA 50-542),  
Amoxil<sup>®</sup> (amoxicillin) 500 mg and 875 mg Tablets (NDA 50-754),  
Amoxil<sup>®</sup> (amoxicillin) for Oral Suspension (NDA 50-760), and  
Amoxil<sup>®</sup> (amoxicillin) 200 mg and 400 mg Chewable Tablets (NDA 50-761)

We note that these applications are subject to the exemption provisions contained in section 125(d)(2) of Title I of the FDA Modernization Act of 1997.

We acknowledge receipt of your submissions dated May 12, 2004.

These supplemental applications revise the **ADVERSE REACTIONS** section, **Renal** subsection, and the **OVERDOSAGE** section of the labeling to add information about the occurrence of crystalluria.

We have completed our review of these applications, as amended. These applications are approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

The final printed labeling (FPL) must be identical to the submitted labeling (text for the package insert dated May 12, 2004), and must be formatted in accordance with the requirements of 21 CFR 201.66.

Please submit the copies of final printed labeling (FPL) electronically to each application according to the Guidance for Industry titled "Providing Regulatory Submissions in Electronic Format – NDA". Alternatively, you may submit 20 paper copies of the FPL as soon as it is available, in no case more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved supplement NDA 50-542/S-022, NDA 50-754/S-009, NDA 50-760/S-008, and NDA 50-761/S-008". Approval of these submissions by FDA is not required before the labeling is used. If a letter communicating important information about these drug products (i.e., a "Dear Health Care

NDA 50-542/S-022  
NDA 50-754/S-009  
NDA 50-760/S-008  
NDA 50-761/S-008  
Page 2

Professional" letter) is issued to physicians and others responsible for patient care, we request that you submit a copy of the letter to these NDA's and a copy to the following address:

MEDWATCH, HF-2  
FDA  
5600 Fishers Lane  
Rockville, MD 20857

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call Susmita Samanta, M.D., Regulatory Project Manager, at (301) 827-2125.

Sincerely,

*{See appended electronic signature page}*

Janice M. Soreth, M.D.  
Director  
Division of Anti-Infective Drug Products  
Office of Drug Evaluation IV  
Center for Drug Evaluation and Research

-----  
**This is a representation of an electronic record that was signed electronically and  
this page is the manifestation of the electronic signature.**  
-----

/s/

-----  
Janice Soreth

7/13/04 06:19:35 PM